Abivax Shares Rise After FDA Clears Path for NDA Submission on Obefazimod
Abivax shares climbed after the company said it had completed a pre-New Drug Application meeting with the U.S. Food and Drug Administration for obefazimod, its lead ulcerative colitis candidate. The FDA signaled full alignment on the planned NDA submission strategy and the dossier's content and format, removing a key procedural uncertainty. Abivax …